[Featured Stock] Jinwon Life Sciences Shares Rise on News of Plasmid DNA Supply to the US
Jinwon Life Sciences is showing a sharp rise in the stock market on the 30th. Expectations for improved performance have increased as it has decided to consecutively supply plasmid DNA to U.S. biotech companies.
As of 10:25 a.m., Jinwon Life Sciences is trading at 2,635 KRW, up 15.57% from the previous day's closing price. It rose relatively steeply from the beginning of the session and then slightly corrected after reaching a peak of 2,820 KRW.
Jinwon Life Sciences announced that it signed a supply contract for plasmid DNA worth 2.7 million USD (approximately 3.5 billion KRW) with a U.S. biotech company on the same day. Plasmid DNA is a key raw material for developing cell and gene therapies, and demand has been increasing recently as the development of cell and gene therapies expands.
Hot Picks Today
"Are You Okay, Dad? Brother?"... 1 in 18 Men Deficient, U.S. Military to Begin Annual Screenings
- Supplementary Measures Introduced for Samsung Electronics and SK hynix Leveraged ETFs... Stricter '30 Million Won Cash Deposit' Requirement (Update)
- “A Major Row Over a Single Egg”…The ‘Side Dish Dispute’ in School Meals
- "Despite Fears of Collapse Without Chinese Tourists... Koreans Become Japan’s Tourism Saviors"
- "Is Haaland a Woman?"... Global Buzz Over Lookalikes and Signature Walk
On the 24th, Jinwon Life Sciences also signed a contract to supply plasmid DNA worth 3.62 million USD (approximately 5 billion KRW) to a U.S. company. As the supply of plasmid DNA continues to expand, expectations for improved performance are growing.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
